U.S. patents available from 1976 to present.
U.S. patent applications available from 2005 to present.

Topical antibiotic composition for treatment of eye infection

Patent 6551584 Issued on April 22, 2003. Estimated Expiration Date: Icon_subject October 10, 2021. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Patent References

3453259

3863633

3867519

3868445

3914402

Bioerodible ocular device
Patent #: 3960150
Issued on: 06/01/1976
Inventor: Hussain ,   et al.

Ocular drug delivery device
Patent #: 3963025
Issued on: 06/15/1976
Inventor: Whitaker ,   et al.

Method and therapeutic system for treating aqueous deficient dry eye
Patent #: 3991759
Issued on: 11/16/1976
Inventor: Urquhart

Ocular drug delivery device
Patent #: 4014335
Issued on: 03/29/1977
Inventor: Arnold

Ocular therapeutic system with selected membranes for administering ophthalmic drug
Patent #: 4057619
Issued on: 11/08/1977
Inventor: Higuchi ,   et al.

More ...

Inventors

Assignee

Application

No. 974598 filed on 10/10/2001

US Classes:

424/78.04Ophthalmic preparation

Examiners

Primary: Azpuru, Carlos

Attorney, Agent or Firm

Foreign Patent References

  • 0424 043 EP. 05/11/1993
  • WO 95/03784 WO. 02/11/1995
  • WO 96/06581 WO. 03/11/1996
  • WO 96/32135 WO. 10/11/1996
  • WO 98/55148 WO. 12/11/1998
  • WO 98/58677 WO. 12/11/1998
  • WO 99/24396 WO. 05/11/1999
  • WO 99/43333 WO. 09/11/1999
  • WO 00/03710 WO. 01/11/2012
  • WO 00/18387 WO. 04/11/2012
  • WO 01/19366 WO. 03/11/2012

International Class

A61K 031/74

Abstract

There is provided a pharmaceutical composition suitable for topical administration to an eye, the composition comprising as active agent at least one oxazolidinone antibacterial drug, for example linezolid, in a concentration effective for treatment and/or prophylaxis of a gram-positive bacterial infection of an eye, and at least one ophthalmically acceptable excipient ingredient that reduces a rate of removal of the composition from the eye by lacrimation such that the composition has an effective residence time in the eye of about 2 to about 24 hours. The composition is, for example, an in situ gellable solution, suspension or solution/suspension.

Other References

  • Rajewski & Stella. Journal of Pharmaceutical Sciences. 85, 1155-1159. (1996)
  • Loftsson. Pharmazie. 53, 733-740. (1998)
  • Sorensen & Jensen. Acta Ophthalmol. 57, 564-581. (1979
PatentsPlus Images
Enhanced PDF formats
loading...
PatentsPlus: add to cart
PatentsPlus: add to cartSearch-enhanced full patent PDF image
$9.95more info
PatentsPlus: add to cart
PatentsPlus: add to cartIntelligent turbocharged patent PDFs with marked up images
$18.95more info
 
Sign InRegister
Username  
Password   
forgot password?